Navigation Links
Preliminary Phase 2 Results of R788 in Lymphoma Show Benefit in Diffuse Large B-Cell and SLL/CLL
Date:6/3/2008

10 6 60% 0

(): # patients enrolled

* NE: Non-Evaluable because of withdrawal due to adverse events or

non-compliance with protocol

** Other NHL patients include 10 with SLL/CLL, 8 with Mantle Cell Lymphoma

(MCL), 3 with MALT, and 1 with Lymphoplasmacystic

At two months of therapy, 53 of the 59 patients were evaluated. Five patients (8% of enrolled) were withdrawn due to possibly related adverse events such as cytopenias and diarrhea, and one for non-compliance. Overall, as of January 15th, 44% of patients had been in the trial for over 7 months without progression of disease. The study is continuing and further results over longer periods of treatment will be available later in the year.

Study Design

The study was conducted in two Phases. In Phase 1, a small group of patients were studied and the 200 mg PO bid (oral, twice daily) dose was selected for further study. In Phase 2, 59 patients with B-cell NHL were enrolled and were given R788. Prior to enrollment, all patients had received various standard of care treatments for their disease, including CHOP (a drug combination) and possibly Rituxan, and had failed to respond to those therapies or suffered a relapse of the disease. The median age was 62 years old. Roughly equal numbers of patients were enrolled based on their subtype of lymphoma, which included: DLBCL, follicular lymphoma (FL) and other non-Hodgkin's lymphomas (specifically - SLL/CLL, MCL, MALT, and lymphoplasmacytic).

B-cell Lymphoma and Syk Inhibition

Lymphoma is the name given to a variety of blood cancers that result when lymphocytes, or white blood cells, grow uncontrollably and build up in the lymphatic system and bone marrow giving rise to malignant tumors. The uncontrolled growth is, in part, mediated by the Syk enzyme, which signals the growth/survive mechanism of the aberrant cells. By inhibiting Syk, that signal is curtailed and the
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
5. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
8. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
9. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Inc. (Vanda) (NASDAQ: VNDA ) today announced that ... of the Year by the Tech Council of ... 25 th Annual Tech Awards Celebration held in ... the leaders and innovators in the technology and life science ... regions. "We are deeply honored to receive ...
(Date:5/23/2013)... Nephros, Inc. (OTC Bulletin Board: ... develops and sells high performance liquid purification ultrafilters, announced ... addition, the concurrent temporary reduction in exercise price for ... 2013. Nephros estimates that it will receive ... A portion of the proceeds will be used for ...
(Date:5/23/2013)... , May 23, 2013  Hadasit Bio-Holdings Ltd. ... of biotech companies, based on intellectual property developed ... Israel ,s foremost medical research center, today ... Ltd., received significant funding from the Israeli Ministry ... Scientist (OCS) to support product development and advance ...
Breaking Medicine Technology:Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... Nov. 1, 2010 LitePoint Corporation, the leader in ... Health Alliance, along with other technology leaders. ... of personal healthcare and to establish a system of ... for all people. "Wireless will be ...
... /PRNewswire-Asia-FirstCall/ -- China Nepstar Chain Drugstore Ltd. (NYSE: ... largest drugstore chain in China based on the number ... will report its third quarter 2010 financial results on ... The Company will host a conference call, to ...
Cached Medicine Technology:LitePoint Joins Continua Health Alliance 2China Nepstar Chain Drugstore to Report Third Quarter 2010 Financial Results on November 17, 2010 2
(Date:5/24/2013)... City, Utah (PRWEB) May 24, 2013 ... , with exciting new enhancements for instructors and students. ... stay more focused through personalize learning plan templates, targeted ... AnatomyOne release provides 500 new assessment questions, 5,000 searchable ... review notes. , AnatomyOne 2.0 is the ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Dwell ... VP, Brandon Huff as Executive Vice President of Digital ... business units, which represented a large portion of Yahoo's ... growth as Dwell develops a fully-integrated commerce unit to ... of experience monetizing digital content for leading firms in ...
(Date:5/24/2013)... News) -- Low-income, minority parents have more realistic ... more open to vaccinating their daughters against the ... study contends. Conversely, white, middle-class parents are ... daughters, according to researchers from the Boston University ... get an HPV-related cancer each year, many of ...
(Date:5/24/2013)... 2013 The Dictation Source recently added ... clients. As a result of its National marketing efforts, ... 20 states around the nation. , Since 1991, The ... to the healthcare industry . Dictation Source is owned ... years of clinical work experience to provide the solutions ...
(Date:5/24/2013)... 24 (HealthDay News) -- About one in five parents ... take up smoking, drinking or illicit drug use, a ... say experts at the Substance Abuse and Mental Health ... are actually one of the most influential forces helping ... "Surveys of teens repeatedly show that parents can ...
Breaking Medicine News(10 mins):Health News:Amirsys AnatomyOne 2.0 Delivers Personalized Learning Plans 2Health News:Yahoo Commerce Head Joins Leadership at Dwell Media 2Health News:Low-Income, Minority Parents More Open to HPV Vaccine for Girls, Study Says 2Health News:The Dictation Source Signs Two National Hospital Chains 2Health News:The Dictation Source Signs Two National Hospital Chains 3Health News:Parents Underestimate Influence Over Teens' Substance Abuse: Survey 2
... Myeloma ( www.ManagingMyeloma.com ), an accredited ... for fellows in oncology to win a scholarship to ... Meeting in New Orleans, Louisiana. The scholarship includes registration ... for meals. , During the conference, the ...
... ... designed to inform our users that the life saving medications they or their loved ... ... -- Recently, WarrantyElephant met with the founder of AllergySense.com, Rhonda Lewis, a WarrantyElephant user, ...
... ... knee amputee, and world record holder in over 10 events in running and triathlon set ... Spirit of the Prairie 100 mile Trail Run in Cassoday, Kansas, Ms. Palmerio-Winters not only ... and finished in 8th place overall. , , ...
... ZURICH, Switzerland, October 15 ... 17 and 18 October 2009. Medical staff, but,particularly administrators ... exceptional introduction to the latest achievements,in football medicine and ... all levels of play. , ...
... Calif., Oct. 14 Beckman Coulter, Inc. (NYSE: BEC ... Thursday, October 29, 2009, at 5:00 p.m. ET to discuss ... released after the market closes. , (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ... 516-3365 or (706) 679-3246 and asking for the Beckman Coulter ...
... , TACOMA, Wash., Oct. 14 Spectrum Pension Consultants, a ... to announce that the 2009 Spectrum Open raised over $100,000, ... oncology unit at St. Joseph,s Hospital. , "This event was ... a participation and fundraising perspective. It was incredible to watch ...
Cached Medicine News:Health News:Managing Myeloma Website Announces Fellow Scholarship Program to Attend and Report on Annual American Society of Hematology in New Orleans 2Health News:WarrantyElephant Launches "MediElephant" a New Medication Reminder Service Inspired by WarrantyElephant User Rhonda Lewis, Founder of AllergySense 2Health News:First Female Amputee To Run a 100 Mile Trail Run Wins the Race 2Health News:FIFA Medical Conference, 17 and 18 October 2009 in Zurich 2Health News:FIFA Medical Conference, 17 and 18 October 2009 in Zurich 3Health News:4th Annual Spectrum Open: A Big Success 2
... Record organizes communication and chart information ... practitioners. It also manages orders, procedures, ... that traditionally rely on many people ... With Microsoft Outlook integration, HealthMatics EMR ...
... Description PANALOK is a fully-absorbable soft ... (polylactic acid) material and provides fixation ... The X-ray transparent anchor retains strength ... and eventually absorbs leaving no permanent ...
... The Bio-Anchor implant is molded from Poly ... absorption rate to insure secure fixation throughout ... eliminates implant removal complications because it is ... be over-drilled. The ribbed, press-fit anchor ...
... just got better. How can one of ... Simply by becoming more convenient to use ... arthroscopic. The TwinFix Suture Anchor with Needles ... unique, convenient and timesaving anchor inserter and ...
Medicine Products: